The long‐term horizon: Patients who will remain untreated in the era of triple therapy
Andrew Aronsohn, Donald Jensen – 6 March 2012 – Watch the interview with the authors
A brief history of the treatment of viral hepatitis C
Doris B. Strader, Leonard B. Seeff – 6 March 2012 – Watch the interview with the authors
The new standard of HCV therapy: Retreatment in experienced patients
Naveen Gara, Marc G. Ghany – 6 March 2012 – Watch the interview with the authors
The new standard of HCV therapy: Treatment in therapy‐naive patients
Saurabh Agrawal, Paul Y. Kwo – 6 March 2012 – Watch the interview with the authors
The long‐term horizon: Patients who will remain untreated in the era of triple therapy
Andrew Aronsohn, Donald Jensen – 6 March 2012 – Watch the interview with the authors
The new standard of HCV therapy: Treatment in therapy‐naive patients
Saurabh Agrawal, Paul Y. Kwo – 6 March 2012 – Watch the interview with the authors
Demographics of hepatitis C virus today
Stevan A. Gonzalez, Gary L. Davis – 6 March 2012 – Watch the interview with the authors
Demographics of hepatitis C virus today
Stevan A. Gonzalez, Gary L. Davis – 6 March 2012 – Watch the interview with the authors
The horizon: New targets and new agents
Alison B. Jazwinski, Andrew J. Muir – 6 March 2012 – Watch the interview with the authors
Androgen pathway stimulates MicroRNA‐216a transcription to suppress the tumor suppressor in lung cancer‐1 gene in early hepatocarcinogenesis
Po‐Jen Chen, Shiou‐Hwei Yeh, Wan‐Hsin Liu, Chen‐Ching Lin, Hsuan‐Cheng Huang, Chi‐Ling Chen, Ding‐Shinn Chen, Pei‐Jer Chen – 5 March 2012 – Deregulation of microRNAs (miRNAs) is common in advanced human hepatocellular carcinoma (HCC); however, the ones involved in early carcinogenesis have not yet been investigated. By examining the expression of 22 HCC‐related miRNAs between precancerous and cancerous liver tissues, we found miR‐216a and miR‐224 were significantly up‐regulated, starting from the precancerous stage.